Perception of risk: the state of COX-2 selective inhibitors.

被引：2

作者：

Simon L.S. ^{[1
]}

Strand V. ^{[1
]}

机构：

[1] Harvard Medical School, Beth Israel Deaconess Medical Center, Suite 5A, 110 Francis Street, Boston, 02115, MA

来源：

Current Rheumatology Reports | 2005年 / 7卷 / 3期

关键词：

Celecoxib; Naproxen; Rofecoxib; Etoricoxib; Valdecoxib;

D O I：

10.1007/s11926-996-0032-4

中图分类号：

学科分类号：

摘要：

[No abstract available]

引用

收藏

页码：163 / 166

页数：3

相关论文

共 50 条

[21] Clinical pharmacology of the selective COX-2 inhibitor
Burian, M
Geisslinger, G
ORTHOPADE, 2003, 32 (12): : 1078 - +
[22] Proposed risk of CV events with COX-2 inhibitors debated
Reactions Weekly, 2002, 883 (1) : 6 - 7
[23] Management of inflammatory pain with selective COX-2 inhibitors: Promises and facts
Pedro F. Bejarano
Current Review of Pain, 1999, 3 (6): : 432 - 439
[24] Selective COX-2 inhibitors vs NSAIDs discussed
Reactions Weekly, 2002, 906 (1) : 3 - 3
[25] COX-2 inhibitors differ in TE risk
Reactions Weekly, 2003, 982 (1) : 4 - 4
[26] Structural investigation on the selective COX-2 inhibitors mediated cardiotoxicity: A review
Arora, Mohit
Choudhary, Shalki
Singh, Pankaj Kumar
Sapra, Bharti
Silakar, Om
LIFE SCIENCES, 2020, 251
[27] Similar reductions in the risk of human colon cancer by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors
Randall E Harris
Joanne Beebe-Donk
Galal A Alshafie
BMC Cancer, 8
[28] Rofecoxib: A selective and effective COX-2 inhibitor
不详
Drugs & Therapy Perspectives, 2002, 18 (2) : 1 - 3
[29] Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance
Jeffrey S Borer
Lee S Simon
Arthritis Research & Therapy, 7
[30] COX-2 inhibitors: lower GI bleeding risk but population risk increased?
Reactions Weekly, 2004, 1002 (1) : 3 - 3

← 1 2 3 4 5 →